Vertex Pharma (VRTX) Announces Positive Longer-Term ORKAMBI + KALYDECO Data in CF Progression Modification

Jefferies Reiterates Buy on Vertex Pharma (VRTX) Following Investor Event

Jefferies reiterated a Buy rating and $102.00 price target on Vertex Pharma (NASDAQ: VRTX) following an investor event. Jefferies thought VRTX made a good argument for the viability of their next-gen correctors despite some questions raised about their safety profiles. They pointed out that while the teratogenicity with '440... More